IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4214
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$113K
Tejinder Virk
Akanda Corp. engages in the cultivation, manufacture, and distribution of cannabis products. It intends to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$AKAN AKANDA CORP. | 34 | 25 | 21 | 27 | - | - | -383.1% | -207.0% | 24.9% | -523.8% | -489.6% | 97.5% | 0.0% | 8.0x | $113K | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
AKANDA CORP. (AKAN) receives a "Avoid" rating with a composite score of 33.9/100. It ranks #4214 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Tejinder Virk
Chief Executive Officer
Labor Force
110
25
58
25
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for AKAN
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for AKAN.
View All RatingsImproving capital utilization rates confirmed
High margin volatility — erratic forensic earnings quality
ROE proxy -383.1% (sector -2.5%)
GM 25% vs sector 43%, OM -524% vs sector 1%
Capital turnover N/A
Rev growth 97%, 4yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags AKANDA CORP. with an Avoid rating, assigning a composite score of 33.9/100 and 1 out of 5 stars. Ranked #4214 of 7,333 stocks, AKAN falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
AKAN's quality score of 25/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -383.1% (sector avg: -2.5%), gross margins of 24.9% (sector avg: 42.5%), net margins of -489.6% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
AKAN registers a value score of just 21/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.46x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
With an investment score of 58/100, AKAN exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 97.5% vs. a sector average of 5.9% and a return on assets of -207.0% (sector: -0.1%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
AKANDA CORP. is experiencing notably weak momentum with a score of just 27/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 97.5% year-over-year, while a beta of 0.79 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
AKAN's stability score of 25/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.79 and a debt-to-equity ratio of 8.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
AKAN's short interest factor score of 84/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 8.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $112,566, AKANDA CORP. benefits from the generally lower volatility and deeper liquidity associated with its size class.
AKANDA CORP. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4214 of 7,333 overall (43rd percentile). Key comparisons include ROE of -383.1% trailing the -2.5% sector median and operating margins of -523.8% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While AKAN currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (21) would have the largest impact on the composite score.
ROE 15348% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 41% BELOW SECTOR MEDIAN
Op. Margin 40705% BELOW SECTOR MEDIAN
AUDIT DATA AS OF DEC 31, 2024 (Q3 FY2024)
We rate AKANDA CORP. (AKAN) as Avoid with a composite score of 33.9/100 at a current price of $0.92. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in investment (58th percentile) and momentum (27th percentile), which together account for the majority of the composite score. Offsetting weakness in value (21th percentile) and stability (25th percentile) tempers our overall conviction. We assign a No Moat rating (22/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
AKANDA CORP. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 33.9/100 places it at rank #4214 in our full 7,333-stock universe. At $112,566 in market capitalization, AKANDA CORP. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 97%, though momentum at the 27th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 25% (-17.6pp vs sector) narrow to operating margins of -524% (-525.1pp vs sector) and net margins of -489.6%, yielding a gross-to-net conversion rate of -1965%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.92, AKANDA CORP. is trading at a premium to fundamental value. Our value factor score of 21/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.5x, P/S of 0.6x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Revenue growth of 97% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (8% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 33.9/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -489.6% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (27th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a High uncertainty rating to AKANDA CORP.. Key risk factors include current negative profitability (net margin -489.6%), below-average price stability (25th percentile), weak quality scores (25th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -489.6%); below-average price stability (25th percentile); weak quality scores (25th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 25th percentile and quality factor at the 25th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (8% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate AKANDA CORP.'s capital allocation as Poor. Key concerns include low returns on equity (-383.1%), negative profitability, weak asset returns (ROA -207.0%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — AKANDA CORP. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, AKANDA CORP. receives a Avoid rating with a composite score of 33.9/100 (rank #4214 of 7,333). Our quantitative framework assigns a No Moat (22/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 31/100.
Our analysis does not support a constructive view on AKANDA CORP. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign AKANDA CORP. a meaningful economic moat, scoring 22/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, growth durability, reached only 11.3/20.
The strongest moat sources are growth durability (11.3/20) and financial resilience (7.7/20). Rev growth 97%, 4yr history. Interest coverage N/A. These pillars form the core of AKANDA CORP.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and reinvestment efficiency (1.3/20). ROE proxy -383.1% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect AKANDA CORP.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include robust top-line growth of 97% expanding the revenue base. The margin cascade from 25% gross to -524% operating to -489.6% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 25th percentile.
The margin profile shows gross margins of 25%, operating margins of -524%, net margins of -489.6%. Return metrics include ROE of -383.1% and ROA of -207.0%. Relative to the Manufacturing sector, gross margins are 17.6 percentage points below the sector median of 43%, and ROE of -383.1% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 8%, revenue growth of 97%. The sector median D/E is 0%, putting AKANDA CORP. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Below-average quality (25th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Elevated short interest (84th percentile) indicates that sophisticated market participants are betting against the stock.
Above 50MA
37.18%
Net New Highs
+51081
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") today announced the closing of its previously announced transaction with institutional investors for the purchase and sale of 12 month, convertible promissory notes for an aggregate purchase price of $7.0 million, in a private placement transaction. The Company shall use the proceeds from the sale of the notes for (i) marketing purposes of up to $2.3 million, (ii) working capital and..
Akanda (AKAN) raising $7M via 12-month convertible notes in a private placement closing Jan 21, 2026—see deal terms, use of proceeds & impact.
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results. Fastenal reported first-quarter FY24 sales growth of 1.9% Y/Y to $1.895 billion, missing the consensus of $1.914 billion. The company's first-quarter EPS was 52 cents, missing the consensus of 53 cents. Fastenal shares dipped 6.7% to $69.73 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Rallybio Corporation (NASDAQ: RLYB) shares climbed 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rent the Runway, Inc. (NASDAQ: RENT) shares jumped 74.5% to $12.91 after the company reported mixed fourth-quarter financial results and issued guidance. Eliem Therapeutics, Inc. (NASDAQ: ELYM) jumped 59.6% to $4.2650. The company announced that it entered into a definitive acquisition agreement to acquire Tenet and it also entered into a securities purchase agreement for a $120 million private placement. Akanda Corp. (NASDAQ: AKAN) gained 36% to $0.1632. Akanda, last month, announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry. Alpine Immune Sciences, Inc. (NASDAQ: ALPN) rose 36.6% to $64.25 after Vertex entered into an agreement to acquire the company. Candel Therapeutics, Inc. (NASDAQ: CADL) surged 29.6% to $6.61 after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. Enliven Therapeutics, Inc. (NASDAQ: ELVN) gained 26% to $24.97. Enliven Therapeutics announced proof ...
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share. Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares jumped 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million. Xilio Therapeutics, Inc. (NASDAQ: XLO) gained 146% to $1.58 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing. Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) shares climbed 80% to $1.5395. Biodexa's MTX110 showed promise in extending life expectancy against aggressive brain cancers. Ontrak, Inc. (NASDAQ: OTRK) gained 55% to $0.9239. Binah Capital Group, Inc. (NASDAQ: BCG) gained 48% to $14.05 after dipping more than 20% on Wednesday. Kidpik Corp. (NASDAQ: PIK) gained 40.7% to $4.5999. Kidpik recently regained compliance with the Nasdaq minimum bid price requirement. Allego N.V. (NASDAQ: ALLG) rose 32.8% to $1.7650. Akanda Corp. (NASDAQ: AKAN) gained 28% to $0.2053 after the company announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry. Destiny Tech100 Inc. (NASDAQ: DXYZ) rose 26% to $22.15. REX American Resources Corporation (NYSE: REX) gained 23.2% to $54.15 following upbeat earnings. Nutriband Inc. (NASDAQ: NTRB) gained 23% to $4.98. Nutriband recently provided a clinical and regulatory path overview for its AVERSA Fentanyl patch. Summit Therapeutics Inc. (NASDAQ: ...
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. AbbVie Inc. (NYSE: ABBV) and Landos Biopharma, reported a definitive agreement under which AbbVie will acquire Landos. Landos Biopharma shares jumped 171.2% to $21.70 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Next.e.GO N.V. (NASDAQ: EGOX) shares jumped 85.8% to $0.0730 after falling around 22% on Friday. Altamira Therapeutics Ltd. (NASDAQ: CYTO) shares climbed 70.1% to $2.9255 after the company announced a collaboration with Univercells Group on nanoparticle-delivered mRNA vaccines. MicroAlgo Inc. (NASDAQ: MLGO) climbed 34.3% to $5.40 after declining around 5% on Friday. XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) gained 32.4% to $3.4690. XTL Biopharmaceuticals recently entered into a binding term sheet to acquire all of the issued and outstanding share capital of Social Proxy. Nkarta, Inc. (NASDAQ: NKTX) gained 23.3% to $11.00 after the company priced $240 million underwritten offering. Target Hospitality Corp. (NASDAQ: TH) jumped 21.3% to $10.82 after the company received a buyout offer from TDR Capital. Swvl Holdings Corp. (NASDAQ: SWVL) rose 21.2% to $11.26. Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) surged 21% to $0.6949. Lucid Group, Inc. (NASDAQ: LCID) jumped 18.7% to $3.29 after the company announced a $1 billion investment by an affiliate of PIF. Sagimet Biosciences Inc. (NASDAQ: SGMT) rose 16.9% to $5.27 after the company reported FY results and announced the appointment of Tim Walbert and Paul Hoelscher to its Board of Director. Ocugen, Inc. (NASDAQ: OCGN) jumped 16.4% to $1.9101. The Third Circuit Court of Appeals recently upheld the decision of the Eastern District of Pennsylvania to dismiss with prejudice the consolidated securities class action lawsuits against Ocugen. Flora Growth Corp. (NASDAQ: FLGC) shares gained 15.2% to $1.8206 after surging around 34% on Friday. Forge Global Holdings, Inc. (NYSE: FRGE) shares gained 14.5% to $2.67 after ...